Tri Pointe Homes Named to 2024 List of Fortune World’s Most Admired Companies™
INCLINE VILLAGE, Nev., Jan. 31, 2024 (GLOBE NEWSWIRE) — National homebuilder Tri Pointe Homes® (NYSE: TPH) today announced that it […]
ATHA Energy Discovers High-Priority Electromagnetic Target Coincident With 11.3% U308 Boulder Sample
NORTH BEACON AND NORTH CREST PROJECT HIGHLIGHTS Uriniferous boulder train discovered on the North Beacon Project – with grades of […]
Global Helium Corp. Announces Operational Update and Shares Independent Resource Estimate From First Manyberries Well
CALGARY, Alberta, Jan. 31, 2024 (GLOBE NEWSWIRE) — Global Helium Corp. (“HECO” or the “Company”) (CSE: HECO, OTC: HECOF) is […]
Algernon Pharmaceuticals Receives Notice of Intention to Grant from Chinese Patent Office for Repirinast to Treat CKD
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: […]
Arqit awarded ISO 27001 Certification for Information Security Management
LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) — Arqit Quantum Inc. (Nasdaq: ARQQ, ARQQW) (Arqit), a leader in quantum-safe encryption, has […]
AirSculpt Technologies Announces Fourth Quarter 2023 Earnings Release Date and Conference Call
MIAMI BEACH, Fla., Jan. 31, 2024 (GLOBE NEWSWIRE) — AirSculpt Technologies, Inc. (“AirSculpt”) (NASDAQ: AIRS), a national provider of premium […]
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
WATERTOWN, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing […]
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024
PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming […]
BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325/DB-1305
Designation is based on preliminary safety and efficacy data from an ongoing Phase 1/2 trial in patients with platinum-resistant ovarian […]
Generac Announces Fourth Quarter and Full-Year 2023 Earnings Release Date and Conference Call
WAUKESHA, Wis., Jan. 31, 2024 (GLOBE NEWSWIRE) — Generac Holdings Inc. (“Generac”) (NYSE: GNRC), a leading global designer and manufacturer […]
